Clinical Importance of Speed of Response to Therapy in Childhood Lymphoblastic Leukaemia

References

• Gaynon P., Desai A., Bostrom B., et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia. Cancer 1997; 80: 1717–1726
   PubMed Web of Science ®Google Scholar
• Reiter A., Schrappe M., Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122–3133
   PubMed Web of Science ®Google Scholar
• Nachman J., Sather H., Gaynon P., Lukens J., Wolff L., Trigg M. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. Journal of Clinical Oncology 1997; 15: 2222–2230
   PubMed Web of Science ®Google Scholar
• Frei E, Karon M, Levin R, et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 1965; 26: 642–656
   PubMed Web of Science ®Google Scholar
• Jacquillat C, Weil M, Gemon MF, et al. Combination therapy in 130 patients with acute lymphoblastic leukemia (protocol 06 LA 66-Paris). Cancer Research 1973; 33: 3278–3284
   PubMed Web of Science ®Google Scholar
• Miller DR, Leikin S, Albo V, Sather H, Karon M. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG 141. Cancer 1983; 51: 1041–1049
   PubMed Web of Science ®Google Scholar
• Miller D, Coccia P, Bleyer W, et al. Early response to induction therapy as a predictor of disease free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Children's Cancer Study Group. Journal of Clinical Oncology 1989; 7: 1807–1815
   PubMed Web of Science ®Google Scholar
• Hutchinson R, Bertolone H, Cooper H, et al. Early marrow response predicts outcome for patients with low risk ALL: results of CCG-1881. Proceedings of the American Society of Clinical Oncology 1994; 13: 319
   Google Scholar
• Rivera G, Raimondi SC, Hancock ML, et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337: 61–66
   PubMed Web of Science ®Google Scholar
• Schrappe M, Reiter A, Sauter S, et al. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow]. [German] Klinische Padiatrie 1994; 206: 208–221
   PubMed Web of Science ®Google Scholar
• Chessells J, Bailey C, Richards S. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council Trial UKALL X. Lancet 1994; 345: 143–148, 1994
   Web of Science ®Google Scholar
• Gaynon PS, Bleyer WA, Steinherz PG, et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavourable presenting features. Medical and Pediatric Oncology 1990; 18: 273–279
   PubMedGoogle Scholar
• Steinherz PG, Gaynon PS, Breneman JC, et al. Cytoreduction and Prognosis in Acute Lymphoblastic Leukemia - The Importance of Early Marrow Response: Report from the Childrens Cancer Group. Journal of Clinical Oncology 1996; 14: 389–398
   PubMed Web of Science ®Google Scholar
• Lilleyman J, Gibson B, Stevens R, et al. Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: clinical importance and the effect of daunorubicin. British Journal of Haematology 1997; 97: 603–606
   PubMed Web of Science ®Google Scholar
• Lilleyman J, Mitchell C, Kinsey S, Richards S. MRC ALL 97, A UK trial comparing dexamethasone with prednisolone and 6-mercaptopurine with 6-thioguanine in children with standard risk lymphoblastic leukaemia. Lancet Website Adopted Protocols 1997; 7–14, http://www.thelan-cet.com
   Google Scholar
• Shultz K, Massing B, Spinelli J, Gaynon P, Wadsworth L. Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia. Medical and Pediatric Oncology 1997; 29: 16–22
   PubMedGoogle Scholar
• Reid M, Roald B. Adequacy of bone marrow trephine biopsy specimens in children. Journal of Clinical Pathology 1996; 49: 226–229
   PubMed Web of Science ®Google Scholar
• Rautonen J, Hovi L, Siimes M. Slow disappearance of peripheral blast cells: an independent risk factor indicating poor prognosis in children with acute lymphoblastic leukemia. Blood 1988; 71: 989–991
   PubMed Web of Science ®Google Scholar
• Gajjar A, Ribeiro R, Hancock ML, et al. Persistence of Circulatinig Blasts after 1 week of Multiagent Chemotherapy confers a Poor Prognosis in Childhood Acute Lymphoblastic Leukemia. Blood 1995; 86: 1292–1295
   PubMed Web of Science ®Google Scholar
• Arico M, Basso G, Mandelli F, et al. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Cancer 1995; 75: 1684–1693
   PubMed Web of Science ®Google Scholar
• Radich J, Thomson B. Advances in the detection of minimal residual disease. Current Opinion in Hematology 1997; 4: 242–247
   PubMedGoogle Scholar
• Brisco M, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantitation of residual disease at the end of induction. Lancet 1994; 343: 196–200
   PubMed Web of Science ®Google Scholar
• Jacquy C, Delepaut B, Van Daele S, et al. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse. British Journal of Haematology 1997; 98: 140–146
   PubMed Web of Science ®Google Scholar
• Steenbergen EJ, Verhagen OJ, van den Berg H, van Leeuwen EF, von dem Borne AE, van der Schoot CE. [Children with acute lymphoblastic leukemia: prognostic significance of polymerase-chain-reaction analysis of minimal residual disease]. [Dutch] Nederlands Tijdschrift voor Geneeskunde 1996; 140: 22–28
   PubMedGoogle Scholar
• Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. New England Journal of Medicine 1997; 336: 317–323
   PubMed Web of Science ®Google Scholar